Akebia Therapeutics Announces Poster Presentations at NKF Spring Clinical Meetings 2025
Akebia Therapeutics (Nasdaq: AKBA) announced its upcoming participation at the National Kidney Foundation Spring Clinical Meetings 2025 (NKF SCM25) in Boston from April 10-13, 2025. The company will present two research posters:
1. A study on cardiovascular risk in patients with DD-CKD comparing Vadadustat vs Darbepoetin Alfa (Poster: G-284)
2. Research on Vadadustat's treatment of anemia comparing older vs younger patients with Dialysis-Dependent-CKD (Poster: G-285)
Dr. Wolfgang Winkelmayer will present the latter study during an oral presentation on April 10, 2025, at 4:00 pm. Attendees can visit Akebia at Booth #1121 in the Exhibit Hall.
Akebia Therapeutics (Nasdaq: AKBA) ha annunciato la sua prossima partecipazione ai National Kidney Foundation Spring Clinical Meetings 2025 (NKF SCM25) a Boston dal 10 al 13 aprile 2025. L'azienda presenterà due poster di ricerca:
1. Uno studio sul rischio cardiovascolare nei pazienti con DD-CKD confrontando Vadadustat e Darbepoetina Alfa (Poster: G-284)
2. Ricerca sul trattamento dell'anemia con Vadadustat confrontando pazienti più anziani e più giovani con CKD Dipendente da Dialisi (Poster: G-285)
Il Dr. Wolfgang Winkelmayer presenterà quest'ultimo studio durante una presentazione orale il 10 aprile 2025, alle 16:00. I partecipanti possono visitare Akebia allo Stand #1121 nella Hall Espositiva.
Akebia Therapeutics (Nasdaq: AKBA) anunció su próxima participación en las National Kidney Foundation Spring Clinical Meetings 2025 (NKF SCM25) en Boston del 10 al 13 de abril de 2025. La compañía presentará dos carteles de investigación:
1. Un estudio sobre el riesgo cardiovascular en pacientes con DD-CKD comparando Vadadustat vs Darbepoetina Alfa (Póster: G-284)
2. Investigación sobre el tratamiento de la anemia con Vadadustat comparando a pacientes mayores y más jóvenes con CKD Dependiente de Diálisis (Póster: G-285)
El Dr. Wolfgang Winkelmayer presentará este último estudio durante una presentación oral el 10 de abril de 2025, a las 4:00 pm. Los asistentes pueden visitar a Akebia en el Stand #1121 en el Salón de Exposiciones.
Akebia Therapeutics (Nasdaq: AKBA)는 2025년 4월 10일부터 13일까지 보스턴에서 열리는 National Kidney Foundation Spring Clinical Meetings 2025 (NKF SCM25)에 참가할 예정이라고 발표했습니다. 이 회사는 두 개의 연구 포스터를 발표할 것입니다:
1. DD-CKD 환자에서 Vadadustat과 Darbepoetin Alfa를 비교한 심혈관 위험에 대한 연구 (포스터: G-284)
2. 투석 의존 CKD 환자에서 노인과 청소년을 비교한 Vadadustat의 빈혈 치료에 대한 연구 (포스터: G-285)
Wolfgang Winkelmayer 박사는 2025년 4월 10일 오후 4시에 구술 발표를 통해 후자의 연구를 발표할 예정입니다. 참석자들은 전시 홀의 Akebia 부스 #1121을 방문할 수 있습니다.
Akebia Therapeutics (Nasdaq: AKBA) a annoncé sa prochaine participation aux National Kidney Foundation Spring Clinical Meetings 2025 (NKF SCM25) à Boston du 10 au 13 avril 2025. L'entreprise présentera deux affiches de recherche :
1. Une étude sur le risque cardiovasculaire chez les patients atteints de DD-CKD comparant Vadadustat et Darbepoetine Alfa (Affiche : G-284)
2. Recherche sur le traitement de l'anémie par Vadadustat comparant les patients plus âgés et plus jeunes atteints de CKD Dépendante de Dialyse (Affiche : G-285)
Le Dr Wolfgang Winkelmayer présentera cette dernière étude lors d'une présentation orale le 10 avril 2025 à 16h00. Les participants peuvent visiter Akebia au stand #1121 dans le hall d'exposition.
Akebia Therapeutics (Nasdaq: AKBA) gab seine bevorstehende Teilnahme an den National Kidney Foundation Spring Clinical Meetings 2025 (NKF SCM25) in Boston vom 10. bis 13. April 2025 bekannt. Das Unternehmen wird zwei Forschungsplakate präsentieren:
1. Eine Studie zum kardiovaskulären Risiko bei Patienten mit DD-CKD im Vergleich von Vadadustat und Darbepoetin Alfa (Plakat: G-284)
2. Forschung zur Behandlung von Anämie mit Vadadustat im Vergleich von älteren und jüngeren Patienten mit dialyseabhängiger CKD (Plakat: G-285)
Dr. Wolfgang Winkelmayer wird die letzte Studie am 10. April 2025 um 16:00 Uhr in einer mündlichen Präsentation vorstellen. Die Teilnehmer können Akebia am Stand #1121 in der Ausstellungshalle besuchen.
- None.
- None.
CAMBRIDGE, Mass., March 25, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it will present data at the National Kidney Foundation Spring Clinical Meetings 2025 (NKF SCM25), which will take place in Boston, MA from April 10-13, 2025.
Akebia-supported posters will be displayed at NKF SCM25 during Exhibit Hall hours.
- Cardiovascular Risk in Patients With DD-CKD Randomized to Vadadustat vs Darbepoetin Alfa With or Without Cardiovascular Disease: Poster: G-284
- Vadadustat for Treatment of Anemia in Older vs Younger Patients With Dialysis-Dependent-CKD: Poster: G-285
On Thursday, April 10, 2025 at 4:00 pm during Oral Poster Presentation: Research 3 at NKF SCM25, Dr. Wolfgang Winkelmayer will present a poster titled “Vadadustat for Treatment of Anemia in Older vs Younger Patients With Dialysis-Dependent-CKD.”
NKF SCM25 attendees can also visit Akebia at Booth #1121 in the Exhibit Hall.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.
Akebia Therapeutics Contact
Mercedes Carrasco
mcarrasco@akebia.com
FAQ
What research will Akebia Therapeutics (AKBA) present at NKF Spring Clinical Meetings 2025?
When and where will Akebia Therapeutics (AKBA) present at NKF SCM25?
What are the poster numbers for AKBA's presentations at NKF SCM25?
Where can attendees find Akebia Therapeutics (AKBA) at NKF SCM25?
